OncoLab Co., Ltd. was selected as a participant in the 2025 Global Startup Project, a national program designed to empower innovative Korean startups to expand internationally and connect with global investors, corporates, and ecosystem leaders.

As part of the program, OncoLab participated in a series of global engagement events in New York City, including KOOM NYC Festival, Bridging Day investor meetups, and PEN-CTA sessions with U.S. state governments and corporate partners. These programs—organized by the Korea Business Angels Association and PEN Ventures Korea—brought together major international stakeholders such as Insight Partners, Takeda, Deutsche Bank, MedSchenker, PwC, and the World Economic Forum, creating opportunities for cross-border collaboration and investment.

Through its participation, OncoLab showcased the ANGel platform, its proprietary precision immuno-oncology technology that integrates antibody conjugation with targeted drug delivery. The company pursued global co-development and licensing partnerships to accelerate clinical translation and pave the way for global market entry.